For patients with severe, chronic back and leg pain, a new high-frequency spinal cord stimulation (SCS) technique provides superior clinical outcomes, compared to conventional low-frequency SCS, reports a clinical trial in the November issue of Neurosurgery.
The new ‘HF10’ technique offers lasting reductions in back and leg pain after other treatments have failed, according to the report by Leonardo Kapural, MD, PhD, Center for Clinical Research and Carolinas Pain Institute, Winston-Salem, North Carolina, and colleagues. They believe that HF10 therapy could have a major impact on the treatment of chronic back and leg pain, and possibly other conditions as well.
The study included 171 patients with moderate to severe back and leg pain that persisted despite other treatments. Treated at 11 US comprehensive pain centres, the patients had chronic pain that had been present for an average of 14 years. Nearly 90% had had previous back surgery; a similar proportion was taking opioid pain medications.
After a trial period, patients were randomly assigned to 1 of 2 SCS techniques, with mild electrical stimulation applied to targeted spinal nerves. One group was treated using HF10, with high-frequency stimulation (10 kilohertz) applied for very short periods. The other group received traditional SCS, with lower-frequency stimulation applied for relatively longer periods.
As previously reported, HF10 provided superior pain relief. At 3 months, scores for back and leg pain decreased by at least half in more than 80% of patients receiving HF10. By comparison, conventional SCS achieved similar responses in back pain for 44% of patients and in leg pain for 55%.
At 2 years’ follow-up, the HF10 group still had higher response rates: 76% versus 49% for back pain and 73% versus 49% for leg pain. On a 0-to-10 rating scale, average back pain score decreased by 5 points with HF10 versus about 3 points for traditional SCS. About 60% of patients receiving HF10 were “very satisfied” with their treatment, compared to 40 percent with conventional SCS.
Although SCS is not a new treatment, it provides more consistent results for leg pain than back pain, and relies on producing overlapping areas of paraesthesia to mask pain. By comparison, HF10 seems to provide greater relief of back pain without inducing areas of numbness. The new study is among the few to directly compare different approaches to SCS in patients with back and leg pain.
Within its limitations, the pragmatic clinical trial supports the superiority of HF10 over conventional SCS for patients with chronic, severe back and leg pain. Extending follow-up to 2 years “provides physicians, patients, and payers with rigorous evidence demonstrating the durability of SCS in treating chronic pain,” Dr. Kapural and coauthors write. They note that the results are “particularly impressive” given the patients’ long history of pain and lack of response to other treatments, including back surgery.
Further research will determine whether HF-10 is useful for other chronic pain problems as well, such as arm and neck pain. Dr. Kapural and colleagues conclude: “The superior and durable results demonstrated in this study are anticipated to lead to improved long-term cost effectiveness and payer acceptance, making this therapy broadly available to patients suffering from chronic pain.”